Gastrointestinal tract
Our area of greatest depth: digestion, barrier, microbiota and the inflammatory response of the epithelium, on models that reproduce what actually happens from the stomach to the intestine.
Physiological areas
GastrointestinalMetabolism and cardiovascular systemDermatologicalNeurologicalOphthalmicMusculoskeletalRespiratoryOralUrologicalVaginalImmune systemWhat you can demonstrate here
If your ingredient or your product acts on digestion, on absorption, on the intestinal barrier or on the balance of the microbiota, this is the area where the evidence is built. It serves those choosing between two raw materials, those who have to support a function in front of a downstream customer, and those who need to know whether what works on the isolated ingredient still works in the finished product.
The models we use
What we measure
- Simulated gastric and intestinal digestion
- Intestinal absorption of ingredients and metabolites
- Bioaccessibility and bioavailability after transit
- Integrity and restoration of the intestinal barrier
- Barrier effect on the oesophageal mucosa and raft formation
- Gastroprotective effect
- Prebiotic activity and prebiotic index
- Antimicrobial activity against intestinal pathogens
- Antibiofilm activity, preventive and curative
- Quantification and viability of probiotics along transit
- Anti-inflammatory activity on gastric and intestinal epithelium
- Antioxidant activity
- Cytotoxicity and tolerability on three-dimensional intestinal tissue
- Inhibition of alpha-amylase and alpha-glucosidase
- Modulation of neuroendocrine peptides, including GLP-1 and GIP (gut-pancreas axis)
What is measured in this area
The endpoints on which evidence is built for the gastrointestinal tract: each answers a different question, and the choice depends on what the product needs to be able to support.
- Bioaccessibility — how much of the ingredient remains available after simulated digestion
- Barrier integrity — the tightness of the intestinal epithelium, measured over time
- Paracellular permeability — passage through the tight junctions, before and after the stimulus
- Barrier protection and repair — protective effect (treatment before the insult) or restorative effect (treatment after it), or both, on human intestinal epithelium differentiated for 21 days. Integrity read by transepithelial electrical resistance (TEER) and by the flux of fluorescent tracers of different sizes; tight-junction proteins (ZO-1 and occludin) by ELISA and immunofluorescence. Insult-only, spontaneous-recovery and reference controls.
- Mucin production — the protective layer that lines the epithelium
- Inflammatory response — cytokines released by the epithelium under stimulus
- Digestive enzymes — activity on alpha-amylase and alpha-glucosidase
- Selective growth — effect on the microbiota, distinguishing what grows from what is contained
- Gut fermentation — anaerobic in vitro fermentation with a defined gut consortium: short-chain fatty acid profile (acetate, propionate, butyrate) and, on the fermented material, GLP-1 and PYY release from enteroendocrine cells.
- Survival through transit — for probiotics, how many arrive alive at the end of the simulation
What you receive
- A report with model, protocol, controls and raw data
- Results per replicate, with mean and spread declared
- A balance of the simulated digestion, phase by phase
- The behaviour of the barrier over time, not only the final value
- A readable comparison between the conditions tested, usable in a technical dossier or in a conversation with a downstream customer
Who it is for, and where to start
- You are choosing between raw materials and need a measured criterion: ingredient validation and valorisation
- You have a finished product and want to know how much stays active in the formulation: supplement valorisation
- You need an ingredient that does not exist yet for this function: development of new ingredients
